Dr. Belldegrun
Surgical Director of the Genitourinary Oncology.
Surgical Oncology, National Institutes of Health,
herBAL RESEARCH SECTION
Norway
Biography
Dr. Belldegrun is Surgical Director of the Genitourinary Oncology.Surgical Oncology, National Institutes of Health,
Research Interest
Adrenal Cancer Bladder Cancer Elevated Prostate Serum Antigen Hematuria Kidney Cancer Prostate Cancer
Publications
-
Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K. Urol Oncol. 2017 Nov 8. pii: S1078-1439(17)30527-6. doi: 10.1016/j.urolonc.2017.09.030. [Epub ahead of print] PMID: 29128421 Similar articles Select item 29103965 2. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K. Urol Oncol. 2017 Nov 2. pii: S1078-1439(17)30544-6. doi: 10.1016/j.urolonc.2017.10.009. [Epub ahead of print] PMID: 29103965 Similar articles Select item 28341495 3. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N. Urol Oncol. 2017 Feb;35(2):39.e1-39.e7. doi: 10.1016/j.urolonc.2016.09.006. Epub 2016 Oct 26. PMID: 28341495 Similar articles Select item 28065395 4. Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility. Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K. Urol Oncol. 2017 May;35(5):272-278. doi: 10.1016/j.urolonc.2016.11.019. Epub 2017 Jan 3. PMID: 28065395 Similar articles Select item 27787547 5. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS. JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419. PMID: 27787547
-
Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K. Urol Oncol. 2017 Nov 8. pii: S1078-1439(17)30527-6. doi: 10.1016/j.urolonc.2017.09.030. [Epub ahead of print] PMID: 29128421 Similar articles Select item 29103965 2. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K. Urol Oncol. 2017 Nov 2. pii: S1078-1439(17)30544-6. doi: 10.1016/j.urolonc.2017.10.009. [Epub ahead of print] PMID: 29103965 Similar articles Select item 28341495 3. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N. Urol Oncol. 2017 Feb;35(2):39.e1-39.e7. doi: 10.1016/j.urolonc.2016.09.006. Epub 2016 Oct 26. PMID: 28341495 Similar articles Select item 28065395 4. Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility. Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K. Urol Oncol. 2017 May;35(5):272-278. doi: 10.1016/j.urolonc.2016.11.019. Epub 2017 Jan 3. PMID: 28065395 Similar articles Select item 27787547 5. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS. JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419. PMID: 27787547
